Immunic
IMUX
65 hedge funds and large institutions have $55.1M invested in Immunic in 2022 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 17 increasing their positions, 21 reducing their positions, and 17 closing their positions.
358% more call options, than puts
Call options by funds: $1.37M | Put options by funds: $300K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.27% less ownership
Funds ownership: 5.98% → 5.71% (-0.27%)
10% less funds holding
Funds holding: 72 → 65 (-7)
13% less capital invested
Capital invested by funds: $63.4M → $55.1M (-$8.24M)
19% less repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 21
41% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 17
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GC
Gratus Capital
Atlanta,
Georgia
|
+$3.15M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$484K |
| 3 |
Walleye Capital
New York
|
+$436K |
| 4 |
Renaissance Technologies
New York
|
+$425K |
| 5 |
Verition Fund Management
Greenwich,
Connecticut
|
+$373K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
-$2.22M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$2.08M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.08M |
| 4 |
Two Sigma Investments
New York
|
-$366K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$292K |
IMUX Hedge Fund Activity: Q3 2022 in Review
65 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q3 2022, worth a combined $55.1M — down 13% from $63.4M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of IMUX and 10 opened new positions — a net loss of 7 holders — while 21 trimmed existing stakes and 17 added.
The largest buyer was Gratus Capital, opening a new position worth an estimated $3.15M. The largest seller was Janus Henderson Group, cutting an estimated $2.22M.
- 65 institutional investors held Immunic (IMUX) as of Q3 2022, down from 72 in Q2 2022.
- Funds reported $55.1M of Immunic stock for Q3 2022, down 13% quarter-over-quarter.
- 10 funds opened new Immunic positions in Q3 2022 and 17 closed out, a net change of -7 holders.
- The largest Immunic buyer in Q3 2022 was Gratus Capital, an estimated $3.15M added.
- The largest Immunic seller in Q3 2022 was Janus Henderson Group, an estimated $2.22M sold.
Based on aggregated 13F filings for Q3 2022.